An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2023-09-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-023-03543-yPMID 37768345PMCID PMC10991109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells

  2023cited by this paper
• Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer

  2023cited by this paper
• High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer

  2023cited by this paper
• ColabFold: making protein folding accessible to all

  2022cited by this paper
• UniProt: the Universal Protein Knowledgebase in 2023

  2022cited by this paper
• Exome sequencing identifies PD‐L2 as a potential predisposition gene for lymphoma

  2022cited by this paper
• IBS 2.0: an upgraded illustrator for the visualization of biological sequences

  2022influential reference
• OUP accepted manuscript

  2022cited by this paper
• Highly accurate protein structure prediction with AlphaFold

  2021cited by this paper
• The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response

  2021cited by this paper
• Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation

  2021cited by this paper
• Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

  2021cited by this paper
• KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.

  2020cited by this paper
• The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

  2020cited by this paper
• Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method

  2019cited by this paper
• A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma

  2019cited by this paper
• A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

  2019cited by this paper
• Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

  2019cited by this paper
• The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals

  2019cited by this paper
• Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

  2018cited by this paper
• Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.

  2018cited by this paper
• The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome

  2018cited by this paper
• Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200

  2018cited by this paper
• Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.

  2017cited by this paper
• Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

  2017cited by this paper
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

  2017cited by this paper
• High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.

  2017cited by this paper
• PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

  2017cited by this paper
• Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

  2017cited by this paper
• A pathology atlas of the human cancer transcriptome

  2017cited by this paper
• Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Non-small Cell Lung Cancer

  2016cited by this paper
• TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data

  2015influential reference
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• The Molecular Signatures Database (MSigDB) hallmark gene set collection.

  2015influential reference
• Molecular and genetic properties of tumors associated with local immune cytolytic activity.

  2015cited by this paper
• Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.

  2015cited by this paper
• The Molecular Signatures Database Hallmark Gene Set Collection

  2015cited by this paper
• PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients

  2014cited by this paper
• The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Cancer immunology.

  2011cited by this paper
• Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

  2010cited by this paper
• Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B

  2010cited by this paper
• The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

  2008cited by this paper
• Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek

  2008cited by this paper
• Inference of macromolecular assemblies from crystalline state.

  2007cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain

  2005cited by this paper
• Cloning and identification of two novel splice variants of human PD-L2.

  2004cited by this paper
• Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

  2002cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper

• A comprehensive review: deep learning-powered revolution in antitumor drug research-exploring multimodal data integration and ethical governance framework

  2026cites this paper
• Serum programmed death ligand 2 is elevated in cats with mammary carcinoma.

  2026cites this paper
• The 3′ end of the tale—neglected isoforms in cancer

  2025cites this paper
• PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors

  2025cites this paper
• Downregulated AhR Expression is Linked with Increased IFN-γ Production and Impaired Immune Checkpoint Upregulation in Vitiligo (MS# JID-2024-1072).

  2025cites this paper
• PD-L1 splice variant-driven soluble PD-L1 secretion promotes immune evasion in gastric cancer.

  2025cites this paper
• Alternative Splicing-Mediated Resistance to Antibody-Based Therapies: Mechanisms and Emerging Therapeutic Strategies

  2025cites this paper
• Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets

  2025cites this paper
• E2-regulated transcriptome complexity revealed by long-read direct RNA sequencing: from isoform discovery to truncated proteins

  2025cites this paper
• Artificial Intelligence Can Predict Personalized Immunotherapy Outcomes in Cancer.

  2025cites this paper
• PD-L2 Expression in Breast Cancer Promotes Tumor Development and Progression

  2024cites this paper
• Evolving Strategies in Cervical Cancer Therapy: A Comprehensive Review Navigating From Molecular Insights to Regulatory Challenges

  2024cites this paper